



## MEDICAL TIPS

DIABIZ TABLETS

Issue I, No. 1, 2022

### **Dapagliflozin does not increase risk of severe UTIs or acute liver injury**

*Johannes C et.al, 81st Annual Scientific Sessions of the American Diabetes Association: abstr. 805-P, 25 Jun 2021*

- Real-world post-authorisation studies collated the data from 03 different cohorts from USA & UK countries between 2012-19 periods.
- The objective was to investigate, the risk of severe UTIs & hospitalized acute liver injury amongst T2DM patients on Dapagliflozin & compared them with patients on other anti-hyperglycemic agents like Metformin, Sulphonylureas & Insulin.
- Pooled data showed that dapagliflozin did not significantly increase the incidence of severe complications of UTIs in women or in men.
- The number of patients hospitalised with dapagliflozin-related acute liver injury was low in all cohorts, and the pooled rate was not significant.

**Dapagliflozin does not appear to increase the risk of severe complications of urinary tract infections (UTIs) or hospitalization for acute liver injury compared with other anti-hyperglycaemics.**

